Article
Urology & Nephrology
Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H. Giles, Milan Hora, Thomas B. Lam, Borje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex
Summary: Recent trial data has shown a survival benefit with combination therapies of cabozantinib plus nivolumab, pembrolizumab plus axitinib, and ipilimumab plus nivolumab in advanced kidney cancer patients. These combinations are now recommended as first-line treatments for advanced kidney cancer.
Article
Medicine, General & Internal
T. K. Choueiri, T. Powles, M. Burotto, B. Escudier, M. T. Bourlon, B. Zurawski, V. M. Oyervides Juarez, J. J. Hsieh, U. Basso, A. Y. Shah, C. Suarez, A. Hamzaj, J. C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J. P. Feregrino, J. Zolnierek, D. Pook, E. R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M. A. Maurer, B. Simsek, F. Ejzykowicz, G. M. Schwab, A. B. Apolo, R. J. Motzer
Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Wang Hao, Wang Ye, Li Li, Zhou Han, Lili Shang, Liao Li, Yike Shen, Aixia Ma
Summary: This study evaluates the health and economic outcomes of nivolumab combined with cabozantinib in the treatment of renal cell carcinoma in China. The results suggest that although the treatment can improve patient survival and quality of life, it is unlikely to be cost-effective due to high medical costs.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
Caroline S. Jansen, Yujin Choi, Sean T. Evans, Rachel Greenwald, Joseph A. Behnke, Caitlin Hartman, Haydn Kissick, Lara R. Harik, Mehmet Asim Bilen
Summary: Extrarenal clear cell renal cell carcinoma (eccRCC) is a rare type of RCC that lacks established consensus guidelines for treatment. This case report demonstrates the successful use of combination therapy with IO+VEGF-TKI, which resulted in an excellent and durable response. This highlights the potential of this treatment option for eccRCC patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
SiNi Li, JianHe Li, LiuBao Peng, YaMin Li, XiaoMin Wan
Summary: A microsimulation decision-analytic model showed that nivolumab plus cabozantinib improved survival outcomes compared to sunitinib in untreated aRCC patients, but replacing first-line treatment with nivolumab plus cabozantinib is unlikely to be cost-effective under the current threshold.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Yann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, Iphigenie Korakis, Friederike Schlurmann, Denis Maillet, Mostefa Bennamoun, Nadine Houede, Delphine Topart, Delphine Borchiellini, Philippe Barthelemy, Raffaele Ratta, Thomas Ryckewaert, Ali Hasbini, Sophie Hans, Sheik Emambux, Sandra Cournier, Elena Braychenko, Reza-Thierry Elaidi, Stephane Oudard
Summary: The CABIR study compared the optimal sequence of using CN and NC after frontline VEGFR-TKI in patients with metastatic renal cell carcinoma (mRCC), and found that the NC sequence had a longer progression-free survival (PFS) compared to the CN sequence. The data suggests that cabozantinib may be more effective than nivolumab in the third-line treatment, possibly due to its ability to overcome resistance to PD-1 blockade.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
David J. Benjamin, Kyle Nolla, David Cella
Summary: Kidney cancer that has spread to organs and other parts of the body outside of the kidney remains a challenging disease to treat. The treatment of advanced kidney cancer has changed over the past decade with the approval of oral therapies called tyrosine kinase inhibitors and more recently immunotherapy, which utilizes the immune system to treat cancer. A new combination therapy employing cabozantinib and nivolumab has been shown to help patients with advanced kidney cancer live longer and have improvements in quality of life. This new combination therapy is now commonly used to treat advanced kidney cancer.
Article
Oncology
Toni K. Choueiri, David F. McDermott, Jaime Merchan, Todd M. Bauer, Robert Figlin, Elisabeth Heath, M. Dror Michaelson, Edward Arrowsmith, Anishka D'Souza, Song Zhao, Ananya Roy, Rodolfo Perini, Donna Vickery, Scott S. Tykodi
Summary: In this study, the combination of belzutifan and cabozantinib showed promising antitumour activity in patients with pretreated clear cell renal cell carcinoma who had previously received immunotherapy. The findings provide rationale for further randomized trials with belzutifan in combination with a VEGFR tyrosine-kinase inhibitor.
Article
Oncology
Kevin K. Zarrabi, Elizabeth Handorf, Benjamin Miron, Matthew R. Zibelman, Fern Anari, Pooja Ghatalia, Elizabeth R. Plimack, Daniel M. Geynisman
Summary: This study compared real-world outcomes in patients with metastatic renal cell carcinoma treated with axitinib/pembrolizumab or ipilimumab/nivolumab. The results showed that patients with IMDC favorable risk disease had better survival when treated with axitinib/pembrolizumab compared to ipilimumab/nivolumab.
Article
Medicine, Research & Experimental
Weiting Liao, Wanting Lei, Mingyang Feng, Yang Yang, Qiuji Wu, Kexun Zhou, Liangliang Bai, Feng Wen, Qiu Li
Summary: Data from the CheckMate 9ER study showed that the combination of nivolumab plus cabozantinib improved progression-free survival and overall survival compared to sunitinib in advanced renal cell carcinoma. However, the cost-effectiveness analysis indicated that nivolumab plus cabozantinib may not be a cost-effective option for first-line treatment of advanced RCC from a US payer's perspective.
ADVANCES IN THERAPY
(2021)
Article
Oncology
Benjamin Duy Tran, Jing Li, Neang Ly, Raffaella Faggioni, Lorin Roskos
Summary: In the CheckMate 9ER trial, intravenous nivolumab plus oral cabozantinib improved PFS in advanced RCC. This exposure-response analysis investigated the relationship between cabozantinib exposure and clinical endpoints.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Nicholas H. Chakiryan, Da David Jiang, Kyle A. Gillis, Elizabeth Green, Ali Hajiran, Lee Hugar, Logan Zemp, Jingsong Zhang, Rohit K. Jain, Jad Chahoud, Philippe E. Spiess, Wade Sexton, Scott M. Gilbert, Brandon J. Manley
Summary: This retrospective study analyzed 5872 patients with metastatic clear cell renal cell carcinoma and found that first-line immunotherapy and combination targeted therapy with immunotherapy were associated with improved overall survival compared to first-line targeted therapy.
Article
Medicine, General & Internal
Sumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, Cristina Suarez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martin Angel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri
Summary: The study aimed to investigate the efficacy of adding atezolizumab to cabozantinib in delaying disease progression and prolonging survival in patients with metastatic renal cell carcinoma. However, the results showed that this combination did not improve clinical outcomes and led to increased toxicity, discouraging the sequential use of immune checkpoint inhibitors in these patients outside of clinical trials.
Article
Oncology
Philippe Barthelemy, Pascale Dutailly, Bryan Qvick, Valerie Perrot, Elena Verzoni
Summary: Cabozantinib plus nivolumab has been approved as a first-line treatment for advanced renal cell carcinoma following the CheckMate 9ER trial. CaboCombo is a non-interventional study designed to evaluate the effectiveness and tolerability of this combination therapy in a real-world setting.
Review
Oncology
Bradley McGregor, Amir Mortazavi, Lisa Cordes, Cristina Salabao, Susan Vandlik, Andrea B. Apolo
Summary: Tyrosine kinase inhibitors combined with immune checkpoint inhibitors have been effective in treating advanced renal cell carcinoma. However, the overlapping adverse events and immune-related adverse events can complicate treatment, necessitating proper management strategies to maintain tolerability.
CANCER TREATMENT REVIEWS
(2022)
Editorial Material
Urology & Nephrology
Umberto Capitanio, Jens Bedke, Laurence Albiges, Alessandro Volpe, Rachel H. Giles, Milan Hora, Lorenzo Marconi, Tobias Klatte, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Borje Ljungberg, Axel Bex
Article
Urology & Nephrology
Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H. Giles, Milan Hora, Borje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex
Summary: In the KEYNOTE-564 trial, adjuvant pembrolizumab showed significant improvement in disease-free survival (DFS) for localized clear-cell renal cell carcinoma (ccRCC) with a high risk of relapse. However, other immunotherapies, such as adjuvant atezolizumab, adjuvant nivolumab plus ipilimumab, and perioperative nivolumab did not meet the primary DFS endpoints. A meta-analysis is not recommended due to heterogeneity. Pembrolizumab remains the only recommended immune checkpoint inhibitor for this indication, but overall survival data are still immature and predictive biomarkers are lacking. Treatment decisions should be made cautiously and with patient involvement.
Article
Oncology
Jiri Ferda, Ondrej Hes, Milan Hora, Eva Ferdova, Jan Pernicky, Vladimir Rudnev, Ladislav Pecen, Ondrej Topolcan, Hynek Mirka
Summary: The uptake of 68Ga-PSMA-11 was found to be correlated with the expression of PSMA, and Gleason patterns 3 and 4 showed a higher correlation with the levels of 68Ga-PSMA-11. No or weak correlations were established with pharmacokinetic parameters.
ANTICANCER RESEARCH
(2023)
Article
Oncology
Ondrej Fiala, Petr Hosek, Hana Korunkova, Milan Hora, Jiri Kolar, Jindra Windrichova, Ondrej Sorejs, Ondrej Topolcan, Ivan Travnicek, Hana Sedlackova, Jindrich Finek
Summary: This study retrospectively analyzed the long-term outcomes of 337 mCRPC patients treated with ENZ or AAP. The study confirmed the efficacy of both ENZ and AAP in mCRPC patients, and identified synchronous metastases, high GS, and visceral metastases as significant adverse prognostic factors.
ANTICANCER RESEARCH
(2023)
Letter
Urology & Nephrology
Umberto Capitanio, Jens Bedke, Laurence Albiges, Alessandro Volpe, Rachel H. Giles, Milan Hora, Lorenzo Marconi, Tobias Klatte, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez Pello, Fabian Hofmann, Teele Kuusk, Riccardo Campi, Rana Tahbaz, Thomas Powles, Boerje Ljungberg, Axel Bex
Editorial Material
Urology & Nephrology
Milan Hora, Laurence Albiges, Jens Bedke, Riccardo Campi, Umberto Capitanio, Rachel H. Giles, Borje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex, Kiril Trpkov
Article
Urology & Nephrology
Nessn H. H. Azawi, Sara Tolouee, Saeed Dabestani
Summary: This retrospective cohort study conducted in Denmark found a low risk of venous thromboembolism (VTE) after partial nephrectomy. However, patients with prior VTE and longer hospital stays are at higher long-term risk and should be considered for thromboprophylaxis.
SCANDINAVIAN JOURNAL OF UROLOGY
(2023)
Article
Medicine, Research & Experimental
Andre Mansinho, Andreia Cruz, Lorenzo Marconi, Cidalia Pinto, Isabel Augusto
Summary: This work provides a summary of guideline recommendations and an expert position on the use of maintenance avelumab therapy for locally advanced or metastatic urothelial carcinoma (UC) based on a review of current international clinical practice guidelines. The expert panel recommends maintenance avelumab therapy in patients with response/stable disease following chemotherapy (regardless of PD-L1 status) for locally advanced or metastatic UC.
ADVANCES IN THERAPY
(2023)
Article
Urology & Nephrology
Lorenzo Marconi, Teele Kuusk, Umberto Capitanio, Christian Beisland, Thomas Lam, Sergio Fernandez Pello, Grant D. Stewart, Tobias Klatte, Alessandro Volpe, Borje Ljungberg, Saeed Dabestani, Axel Bex
Summary: This study evaluated the effectiveness of local treatment for resectable recurrent renal cell carcinoma after surgical treatment of the primary kidney tumor. The results showed that local treatment could improve patients' survival, regardless of the risk of recurrence.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Review
Urology & Nephrology
Katharina Beyer, Christiaan Widdershoven, Lisa M. Wintner, Saeed Dabestani, Lorenzo Marconi, Charlotte Moss, Netty Kinsella, Yuhong Yuan, Rachel H. Giles, Ravi Barod, Mieke Van Hemelrijck, Axel Bex, Patricia Zondervan, Steven MacLennan
Summary: This study investigates the heterogeneity in outcome reporting in effectiveness trials and observational studies in localized renal cell carcinoma. The results show inconsistency in outcome reporting across studies and variability in definitions for conceptually similar outcomes.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
